logo

For the Inventor, By the Inventor

Dolo, Italy

Florian Anton Martin Huber

This inventor holds 11 USPTO granted patents and 1 published patent application and 10 EPO patents. Top assignees: H. Lundbeck A/s, Lundbeck Pharmaceuticals, Italy, Bioei Therapies Corp. Active years: 2011-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Florian Anton Martin Huber. Retrieved from https://idiyas.com/inventor/florian-anton-martin-huber

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 72.7

 

Average Co-Inventor Count = 2.7

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Bolzano Vicentino, IT (2011 - 2014)
  • Venice, IT (2018)
  • Dolo, IT (2013 - 2019)
  • Dollo VE, IT (2020)
  • Dolo VE, IT (2019 - 2022)

Company Filing History:

goldMedal7 out of 513 
 
H. Lundbeck A/s
 patents
silverMedal4 out of 12 
 
Lundbeck Pharmaceuticals, Italy
 patents
bronzeMedal1 out of 1 
 
Bioei Therapies Corp
 patent
where one patent can have more than one assignee

Years Active: 2011-2022

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 11332478 - Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (2022-05-17),
2. 10626123 - Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (2020-04-21),
3. 10385020 - Process intermediates and methods for the preparation of process intermediates for the synthesis of argatroban monohydrate (2019-08-20),
4. 10329264 - Process for the preparation of isocarboxazid (2019-06-25),
5. 9994526 - Process intermediates and methods for the preparation of process intermediates for the synthesis of argatroban monohydrate (2018-06-12),
6. 9975850 - Process for the manufacture of idalopirdine via hydrogenation of an imine (2018-05-22),
7. 8912360 - Methods for preparing ritodrine hydrochloride (2014-12-16),
8. 8754217 - Nalmefene hydrochloride dihydrate (2014-06-17),
9. 8580963 - Method for the manufacturing of naltrexone (2013-11-12),
10. 8530495 - Nalmefene hydrochloride dihydrate (2013-09-10),
11. 8022232 - Method for manufacture of escitalopram (2011-09-20),

Title: Florian Anton Martin Huber: Innovator in Pharmaceutical Synthesis

Introduction

Florian Anton Martin Huber is a notable inventor based in Dolo, Italy. He has made significant contributions to the field of pharmaceutical synthesis, holding a total of 11 patents. His work primarily focuses on innovative processes that enhance the synthesis of complex chemical compounds.

Latest Patents

One of Huber's latest patents involves the manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol, commonly known as gaboxadol. This invention outlines a novel process for synthesizing gaboxadol starting from pyrrolidin-2-one. The method includes a direct approach to obtain key intermediates, such as dimethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-dicarboxylate and diethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-dicarboxylate.

Career Highlights

Throughout his career, Huber has worked with prominent companies in the pharmaceutical industry, including H. Lundbeck A/S and Lundbeck Pharmaceuticals Italy S.p.A. His experience in these organizations has allowed him to develop and refine his innovative approaches to drug synthesis.

Collaborations

Huber has collaborated with several professionals in his field, including Carla De Faveri and Mariano Stivanello. These partnerships have contributed to the advancement of his research and the successful development of his patented processes.

Conclusion

Florian Anton Martin Huber is a distinguished inventor whose work in pharmaceutical synthesis has led to significant advancements in the field. His innovative patents and collaborations reflect his commitment to enhancing drug development processes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…